G

Genelux Corp
D

GNLX

2.64000
USD
0.14
(5.39%)
مغلق
حجم التداول
4,014
الربح لكل سهم
-1
العائد الربحي
-
P/E
-3
حجم السوق
91,180,808
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    B
    BNTX
    -3.740
    (-3.61%)
    99.740 USD
    C
    CODX
    -0.04000
    (-3.64%)
    1.06000 USD
    I
    IBIO
    0.14700
    (6.84%)
    2.29700 USD
    I
    INO
    -0.54000
    (-11.25%)
    4.26000 USD
    MRNA
    MRNA
    -2.950
    (-7.42%)
    36.830 USD
    N
    NVAX
    0.12000
    (1.67%)
    7.32500 USD
    O
    ONTX
    0
    (0%)
    0.000000 USD
    V
    VXRT
    -0.05030
    (-7.97%)
    0.58050 USD
    المزيد
الأخبار

العنوان: Genelux Corp

القطاع: Healthcare
الصناعة: Biotechnology
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.